Archives

6 December 2019 ASX ANNOUNCEMENT Penthrox Marketing Authorisation Application in Russia Medical Developments International Limited (ASX: MVP) announced today that the Russian Ministry of Health has accepted MVP’s Marketing Authorisation Application (MAA) for review. MVP submitted the MAA for Penthrox on 30 September and after a two-month validation period, the Russian Ministry of Health advised […]

21 November 2019 ASX ANNOUNCEMENT Penthrox IND approved in China Medical Developments International Limited (ASX: MVP) is delighted to announce the Chinese National Medical Product Administration (NMPA) has approved the opening of MVP’s Investigative New Drug (IND) application.  This application is a critical step and building block to having Penthrox approved for sale in China. […]

29 October 2019 ASX ANNOUNCEMENT MVP signs new Manufacturing Development Project with CSIRO Medical Developments International Limited (ASX: MVP) is delighted to announce it has signed an extension to the 2017 agreement with Australia’s national science agency, the Commonwealth Scientific and Industrial Research Organisation (CSIRO), to develop new manufacturing technologies for pharmaceutical products. This agreement […]

24 October 2019 ASX Announcement Penthrox® entered in the European Society of Emergency Medicine (“EUSEM”) guidelines as now being recommended and approved as “first-line of treatment” trauma medication. Medical Developments International Ltd (ASX: MVP) is delighted to announce that Penthrox has been included in the new EUSEM guidelines for the “Management of acute pain in […]

23 October 2019 ASX Announcement Penthrox® is launched in Italy Medical Developments International Ltd (ASX: MVP) is delighted to announce that Penthrox has been launched in Italy. MVP CEO Mr. John Sharman said, “We are delighted to finally launch Penthrox in the important European market of Italy.  There has been a number of clinical studies […]

22 October 2019 ASX Announcement Positive study results for Penthrox® demonstrating superiority over Standard of Care for acute trauma pain treatments in patients across Europe Medical Developments International Limited (ASX: MVP) is delighted to announce that data across 11 abstracts of studies conducted throughout Europe and presented at the EUSEM Congress on October 12th to […]

3 June 2019 ASX ANNOUNCEMENT Licensing deal for Penthrox in Australia Medical Developments International Limited (ASX: MVP) is delighted to announce it has reached agreement with Mundipharma Pty Ltd (Mundipharma) for the exclusive distribution rights of Penthrox® in Australia. Mr. John Sharman, Chief Executive Officer of MVP, said: “This is an exciting deal for MVP […]

30 October 2018 ASX Announcement Trading and market update Please refer to the following link for a trading and market update – ASX Announcement – Market and Trading Update

Please refer to the following link for the Chairman’s and CEO’s Address to Shareholders, as provided at the 2018 AGM – ASX Announcement – Chairman’s and CEO’s Address to Shareholders (Final)

11 October 2018 ASX Announcement Penthrox is approved in Saudi Arabia Medical Developments International Limited (ASX:MVP), announce today that Penthrox® has been granted Marketing Authorisation in the Kingdom of Saudi Arabia (KSA). The Marketing Authorisation issued by the Saudi Food and Drug Administration (SFDA), is for Penthrox® to be used for Emergency relief of moderate […]